Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck’s Keytruda Cuts Death Risk by 31 Percent in Esophageal Cancer

Merck & Co. released data from KEYNOTE-181, a Phase III trial of Keytruda as a monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.

Read More »

Statins may help prevent diabetes-related eye problems

Diabetic patients who take statins to treat high cholesterol may get an added benefit: a lower risk of damage to the retina, a new study suggests.

Read More »

Lilly Announces Agreement To Acquire Loxo Oncology

Eli Lilly and Company and Loxo Oncology Inc. announced a definitive agreement for Lilly to acquire Loxo for $235.00 per share in cash, or approximately $8.0 billion.

Read More »

BioNTech teams up with Sanofi to target solid tumors

Germany-based BioNTech extended a three-year-old collaboration with Sanofi as the companies look to co-develop the first cancer immunotherapy candidate for solid tumors.

Read More »

Sprycel Approved in Combination with Chemo in Certain Pediatric Patients with PH+ ALL

Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration expanded the indication for Sprycel tablets to include the treatment of pediatric patients 1 year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.

Read More »

Sanofi Unloads Programs to Acer Therapeutics and MyoKardia

Acer Therapeutics in-licensed the clinical-stage, selective, non-peptide tachykinin NK3 receptor antagonist osanetant from Sanofi. MyoKardia regained global rights to all the programs that the company had inked with Sanofi.

Read More »

Aurobindo Pharma to recall 80 lots of blood pressure medicine valsartan in the US

A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd. will recall 80 lots of medicines containing the blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration.

Read More »

ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2

ProQR Therapeutics N.V. announced that the company received Fast Track designation from the Food and Drug Administration for QR-421a for Usher syndrome type 2.

Read More »

A Record Year: A Look at the Biotech IPOs for Q4 2018

The Nasdaq indicated that there was a record amount of biotech initial public offerings (IPOs) in 2018, totaling around $8.2 billion raised, breaking 2014’s record of $6.5 billion.

Read More »

BioSpace Readers’ Picks: Top 10 Stories of 2018

Here is a look at BioSpace’s top 10 stories of 2018.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!


Ad Right Bottom